December 9th According to Kyodo News Agency on the 9th, the U.S. pharmaceutical giant Pfizer and the Japanese government have reached a basic agreement to supply 120 million doses (60 million copies) of vaccines in the first half of 2021, but it needs to go through domestic clinical trials and review procedures in Japan, and it is expected that the vaccination will be as soon as 2021. It began around March.
According to the Japanese government, Pfizer is carrying out phase I and II clinical trials in Japan, which is equivalent to the initial stage of a three-phase clinical trial.
The person in charge of public relations said that “it is advancing as planned”. British pharmaceutical giant AstraZeneca has also reached an agreement with Japan to provide 120 million doses of vaccine and is implementing domestic clinical trials in Japan.
In addition, the U.S. biotechnology company Modena will also sign a contract with the government to provide 50 million doses of vaccines, but the clinical trial is still in the preparation stage.
Japanese media said that the effect of the vaccine is expected by all parties, but there are also opinions about its safety. At present, it is necessary to collect information about countries that have started vaccination, such as side effects.
It is reported that many of the vaccines under development use new technologies that have not put into practical precedents in the past.